These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 7540934)

  • 21. The Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug resistance.
    Hsiou Y; Ding J; Das K; Clark AD; Boyer PL; Lewi P; Janssen PA; Kleim JP; Rösner M; Hughes SH; Arnold E
    J Mol Biol; 2001 Jun; 309(2):437-45. PubMed ID: 11371163
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human immunodeficiency virus 1 (HIV-1)-specific reverse transcriptase (RT) inhibitors may suppress the replication of specific drug-resistant (E138K)RT HIV-1 mutants or select for highly resistant (Y181C-->C181I)RT HIV-1 mutants.
    Balzarini J; Karlsson A; Sardana VV; Emini EA; Camarasa MJ; De Clercq E
    Proc Natl Acad Sci U S A; 1994 Jul; 91(14):6599-603. PubMed ID: 7517553
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 2.2 A resolution structure of the amino-terminal half of HIV-1 reverse transcriptase (fingers and palm subdomains).
    Unge T; Knight S; Bhikhabhai R; Lövgren S; Dauter Z; Wilson K; Strandberg B
    Structure; 1994 Oct; 2(10):953-61. PubMed ID: 7532533
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HIV-1 reverse transcriptase resistance to nonnucleoside inhibitors.
    Spence RA; Anderson KS; Johnson KA
    Biochemistry; 1996 Jan; 35(3):1054-63. PubMed ID: 8547241
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Crystal structures of clinically relevant Lys103Asn/Tyr181Cys double mutant HIV-1 reverse transcriptase in complexes with ATP and non-nucleoside inhibitor HBY 097.
    Das K; Sarafianos SG; Clark AD; Boyer PL; Hughes SH; Arnold E
    J Mol Biol; 2007 Jan; 365(1):77-89. PubMed ID: 17056061
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Resistance to 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives is generated by mutations at multiple sites in the HIV-1 reverse transcriptase.
    Buckheit RW; Fliakas-Boltz V; Yeagy-Bargo S; Weislow O; Mayers DL; Boyer PL; Hughes SH; Pan BC; Chu SH; Bader JP
    Virology; 1995 Jun; 210(1):186-93. PubMed ID: 7540784
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase.
    Ren J; Milton J; Weaver KL; Short SA; Stuart DI; Stammers DK
    Structure; 2000 Oct; 8(10):1089-94. PubMed ID: 11080630
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Structural mechanisms of drug resistance for mutations at codons 181 and 188 in HIV-1 reverse transcriptase and the improved resilience of second generation non-nucleoside inhibitors.
    Ren J; Nichols C; Bird L; Chamberlain P; Weaver K; Short S; Stuart DI; Stammers DK
    J Mol Biol; 2001 Sep; 312(4):795-805. PubMed ID: 11575933
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of the amino acid in the human immunodeficiency virus type 1 reverse transcriptase involved in the pyrophosphate binding of antiviral nucleoside triphosphate analogs and phosphonoformate. Implications for multiple drug resistance.
    Im GJ; Tramontano E; Gonzalez CJ; Cheng YC
    Biochem Pharmacol; 1993 Dec; 46(12):2307-13. PubMed ID: 7506027
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nucleoside drug resistance in HIV-1 reverse transcriptase.
    Yadav PN; Yadav JS; Modak MJ
    Nat Struct Biol; 1995 Mar; 2(3):193-5. PubMed ID: 7539709
    [No Abstract]   [Full Text] [Related]  

  • 31. Structure-based design of non-nucleoside reverse transcriptase inhibitors of drug-resistant human immunodeficiency virus.
    Mao C; Sudbeck EA; Venkatachalam TK; Uckun FM
    Antivir Chem Chemother; 1999 Sep; 10(5):233-40. PubMed ID: 10574178
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Crystal structures of an N-terminal fragment from Moloney murine leukemia virus reverse transcriptase complexed with nucleic acid: functional implications for template-primer binding to the fingers domain.
    Najmudin S; Coté ML; Sun D; Yohannan S; Montano SP; Gu J; Georgiadis MM
    J Mol Biol; 2000 Feb; 296(2):613-32. PubMed ID: 10669612
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A dipyrido [2,3-b:3',2'-f]azepine analog of the HIV-1 reverse transcriptase inhibitor nevirapine.
    Dyatkin AB; Brickwood JR; Proudfoot JR
    Bioorg Med Chem Lett; 1998 Aug; 8(16):2169-72. PubMed ID: 9873507
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Crystal structures of HIV-1 reverse transcriptases mutated at codons 100, 106 and 108 and mechanisms of resistance to non-nucleoside inhibitors.
    Ren J; Nichols CE; Chamberlain PP; Weaver KL; Short SA; Stammers DK
    J Mol Biol; 2004 Feb; 336(3):569-78. PubMed ID: 15095972
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Insights into DNA polymerization mechanisms from structure and function analysis of HIV-1 reverse transcriptase.
    Patel PH; Jacobo-Molina A; Ding J; Tantillo C; Clark AD; Raag R; Nanni RG; Hughes SH; Arnold E
    Biochemistry; 1995 Apr; 34(16):5351-63. PubMed ID: 7537090
    [TBL] [Abstract][Full Text] [Related]  

  • 36. All-atom models for the non-nucleoside binding site of HIV-1 reverse transcriptase complexed with inhibitors: a 3D QSAR approach.
    Gussio R; Pattabiraman N; Zaharevitz DW; Kellogg GE; Topol IA; Rice WG; Schaeffer CA; Erickson JW; Burt SK
    J Med Chem; 1996 Apr; 39(8):1645-50. PubMed ID: 8648604
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture.
    Richman D; Shih CK; Lowy I; Rose J; Prodanovich P; Goff S; Griffin J
    Proc Natl Acad Sci U S A; 1991 Dec; 88(24):11241-5. PubMed ID: 1722324
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel, non-nucleoside inhibitor of HIV-1 reverse transcriptase.
    Merluzzi VJ; Rosenthal AS
    Adv Exp Med Biol; 1992; 312():89-94. PubMed ID: 1381140
    [No Abstract]   [Full Text] [Related]  

  • 39. Sensitivity of (138 Glu-->Lys) mutated human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) to HIV-1-specific RT inhibitors.
    Balzarini J; Kleim JP; Riess G; Camarasa MJ; De Clercq E; Karlsson A
    Biochem Biophys Res Commun; 1994 Jun; 201(3):1305-12. PubMed ID: 7517668
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor.
    Kohlstaedt LA; Wang J; Friedman JM; Rice PA; Steitz TA
    Science; 1992 Jun; 256(5065):1783-90. PubMed ID: 1377403
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.